Applying the syndemic framework to cancer research for effective cancer control in LMICs

Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC

Pegargiminase-pemetrexed-platinum triplet therapy prolongs survival in non-epithelioid pleural mesothelioma

The multidisciplinary team (MDT) approach and quality of care

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC

Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours

Does the mind matter in cancer? Experiences of Psycho-oncology from a tertiary cancer centre in South Asia

Challenge mission to improve access to quality cancer care

Choosing Wisely: An important step in the right direction

Cancer situation in Cambodia

VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers